

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q96347

Nobuhiko FUSHIMI, et al.

Appln. No.: 10/591,403

Group Art Unit: 1623

Confirmation No.: 9581

Examiner: Jonathan S. Lau

Filed: September 1, 2006

For: FUSED HETEROCYCLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING
THE SAME, AND MEDICINAL USE THEREOF

SUBSTANCE OF INTERVIEW

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

REMARKS

A telephone interview was conducted between the undersigned and Examiner Lau on February 16, 2010.

There was no exhibit shown or demonstration conducted, the only claim discussed was claim 18 where it was agreed to delete the "prodrug" language, and no prior art was discussed.

A discussion was had regarding the amendment to page 10, line 14, to add the language which the Examiner added by way of Examiner's Amendment. It was pointed out that the preceding language "one of R¹ and R⁴ represents" on page 7, line 2 and in claim 1 provided support and good basis was provided by page 36, lines 3-5; page 46, line 12 to page 47, line 2; page 47, lines 7-10 and page 47, line 21 to page 48, line 2.


Agreement was reached and no other issues were discussed.

SUBSTANCE OF INTERVIEW Attorney Docket No.: Q96347
U.S. Application No.: 10/591,403

It is respectfully submitted that the instant STATEMENT OF SUBSTANCE OF INTERVIEW complies with the requirements of 37 C.F.R. §§1.2 and 1.133 and MPEP §713.04.

It is believed that no petition or fee is required. However, if the USPTO deems otherwise, Applicant hereby petitions for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,


Peter D. Olexy
Registration No. 24,513

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 10, 2010